Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented

ver the past decade, transthyretin cardiac amyloidosis (ATTR-CM) has rapidly emerged as an increasingly diagnosed cause of heart failure (HF) among older adults, predominantly those with HF with preserved ejection fraction.Although still frequently classified as a rare disease, there is mounting evidence that ATTR-CM is not as "rare" as it has been historically described.Because of the development of effective disease-modifying therapies, such as transthyretin stabilizers, early and accurate identification of ATTR-CM is essential, as these treatments can reduce HF hospitalizations, slow the decline in loss of quality of life, and extend survival.